Cumulus Neuroscience Shares Data at AAIC 2024 and Tech & Dementia Preconference

Cumulus Neuroscience has made significant strides in the field of Alzheimer's disease research by presenting groundbreaking data from their CNS-101 study at the Alzheimer's Association International Conference 2024 in Philadelphia. The study, conducted in partnership with the University of Cambridge, utilized the Cumulus NeuLogiq™ Platform to collect data through frequent at-home sampling, demonstrating the feasibility and effectiveness of this innovative approach.

The CNS-101 study involved patients with Alzheimer's dementia (AD) and healthy controls, who were tasked with performing various digital measurements and assessments at home. Despite initial concerns about using technology in a home setting, compliance rates were high, with AD patients and healthy controls achieving 79.2% and 89.9% adherence, respectively. Over the course of the study, participants reported a 150% increase in ease of use and a 24% reduction in the need for assistance, indicating the platform's potential for seamless integration into daily routines. Notably, the dropout rates were relatively low, with 27% for AD patients and 10% for healthy controls, even with the intensive nature of the year-long study protocol.

Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus, emphasized the limitations of traditional clinic-based biomarkers, which are not scalable and often lack objectivity. He highlighted that the CNS-101 study, executed in collaboration with the Cumulus Pharma Advisory Group, validated that patients with Alzheimer's dementia are willing and able to participate in longitudinal clinical studies conducted at home. The NeuLogiq platform, which includes an FDA-cleared EEG headset, proved to be user-friendly and suitable for repeated use, leading to high adherence and low dropout rates.

Alzheimer's disease is a progressive condition that impairs brain function, memory, and cognitive abilities, affecting millions globally. Symptoms gradually worsen over time, including memory loss, confusion, communication difficulties, mood swings, and behavioral changes. Currently, there is no known cure for Alzheimer's disease.

A second poster presented at the conference showcased that machine-learning analysis of real-world multimodal data collected at home can detect dementia as accurately as the traditional Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). This data demonstrated that behavioral and EEG-based measures strongly aligned with established benchmarks, providing early evidence of the construct validity and technical feasibility of the NeuLogiq platform. This approach enables precise measurement of disease severity on a large scale.

In the CNS-101 study, 59 patients with AD and a matched cohort of 60 healthy controls were recruited across seven sites in the UK, including Cambridge and Oxford Universities. Over a 12-month period, participants completed repeated home-based sessions using the NeuLogiq platform during the day and wore a sleep EEG device at night. Day sessions, which lasted approximately 30 minutes, included eight behavioral assessments on a mobile tablet, while synchronized EEG was recorded using a 16-lead headset. The study followed a staggered longitudinal protocol with burst sampling tapering to periodic sampling throughout the year. Benchmarked paper-based assessments and self-reported usability data were collected at months 0, 6, and 12, along with blood plasma samples at months 6 and 12 for future biomarker analysis.

Cumulus Neuroscience's NeuLogiq™ platform aims to revolutionize CNS clinical trials and patient care by enabling remote monitoring of patients across various domains of brain function. The platform, developed in collaboration with leading pharmaceutical companies, allows for decentralized trials and is already making a significant impact on the development of therapies for Alzheimer's disease, depression, and schizophrenia. By combining patented technology, in-house expertise, and key industry partnerships, Cumulus captures large amounts of real-world clinical data to provide robust and cost-effective assessments of CNS treatment outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!